Navigation Links
Hotspur Technology's Novel 3-in-1 Angioplasty Balloon Successfully Achieves First Commercial Deployment
Date:12/23/2010

MOUNTAIN VIEW, Calif., Dec. 23, 2010 /PRNewswire/ -- Hotspur Technologies, Inc. announced today that Guy Mayeda, MD, interventional cardiologist at Good Samaritan Hospital in Los Angeles, California, performed the first commercial deployment of the company's IQCath™ Balloon Dilatation Catheter. This new device enables, for the first time, performance of three complex vascular procedures with one single catheter, potentially reducing procedure time and expense for both patients and medical professionals.

"The IQCath brings much needed efficiency and innovation to dialysis graft revascularization procedures. The ability to perform balloon angioplasty, embolectomy, local drug delivery, and angiography with a single device should shorten procedure times, as well as reduce radiation exposure to both the operator and patients," said Dr. Mayeda.

The IQCath is a three-in-one device that allows physicians to perform high-pressure angioplasty, inject fluids such as contrast, and perform embolectomy while maintaining guidewire position. During this procedure, Dr. Mayeda brought the 5mm balloon to its RBP of 16 atmospheres ten times and performed five intermittent contrast injections while utilizing the same catheter. In the past, in these types of medical procedures, physicians typically have had to use multiple catheters to open the blood vessels, which can be time-consuming and expensive. Hotspur's products enable insertion of only one catheter for the entire procedure.

The IQCath is one of Hotspur's first three devices that have received 510(k) clearance from the U.S. Food and Drug Administration. These three new Hotspur devices are focused on solving some of the key challenges associated with restoring blood flow to blocked or low flow dialysis access grafts and fistulaes and peripheral vessels.

"We have heard from physicians that they need devices that are purpose-designed for the many peripheral access procedures they perform regularly – rather than having to repurpose a variety of legacy devices designed for other procedures," said Gwen Watanabe, president and CEO of Hotspur. "We are committed to responding to this need and bringing high quality and efficient devices to a very broad and currently underserved market." Watanabe indicated that, based on the company's analysis, there are as many of 800,000 procedures performed annually that could benefit from this multi- purpose approach to catheter design for the peripheral access market.

In addition to the IQCath, Hotspur has also gained 510(k) clearance for two additional innovative balloon technologies. The GPSCath™ Balloon Dilatation Catheter follows the lead of the IQCath Balloon Dilatation Catheter as a specialty two-in-one device that allows the physician to conduct angioplasty and inject fluid while maintaining guidewire position. The Keeper™ Embolectomy Catheter is another two-in-one device which integrates an embolectomy balloon with the ability to inject physician-specified fluids while maintaining guidewire position.

These products are commercially available and are based on Hotspur's unique technologies designed to potentially make dialysis access and peripheral vascular interventions that are less invasive for patients, less expensive and more efficient for staff and facilities.

The foundation of all three of Hotspur's first commercial devices is a unique and groundbreaking technology, known as the VisioValve™ injection system. This innovation utilizes a proprietary valve system that allows a physician to perform angioplasty or clot removal and perform an injection of physician-specified fluids without having to remove the guidewire or exchange devices. Hotspur expects to develop a variety of other treatment devices based on this technology.

AoutHotspurTechnologiesFounded in 2008 and located in Mountain View, California, Hotspur Technologies (www.hotspur-inc.com) is a leading developer of catheter-based technologies aimed at restoring blood flow for patients with obstructed vessels. The company's products are based on a unique technology that opens blood vessels more efficiently and less invasively. The firm's VisioValve technology serves as a launching point to improve patient outcome and physician efficiency. Hotspur is privately held. Its investors include ONSET Ventures, Finistere Ventures, BioStar Ventures, Saratoga Ventures, Incept, G- Level, and Versant Ventures.

Editors, note: All trademarks and registered trademarks are those of their respective companies. Additional background information is available at www.roeder-johnson.com.For more press information contact:For more customer information contact:Abigail Johnson

Hotspur Technologies Roeder-Johnson Corporation

Mountain View, CA(650) 802-1850

(650) 969-3150http://email.roeder-johnson.com

info@hotspur-inc.com
'/>"/>

SOURCE Hotspur Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Announces Novel Oral Contraceptive Approval
2. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
3. Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders
4. Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders
5. InfraReDx Announces Publication of a Case Report in Circulation Highlighting Novel Clinical Finding with LipiScan™ Coronary Imaging System
6. Audax Medical, Inc. Secures Exclusive Rights to Novel Osteobiologic Nanotechnology
7. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
8. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
9. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
10. The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion
11. Cocrystal Discovery Receives Awards for Its Novel Antiviral Drug Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- Boehringer Ingelheim announced today that it has been recognized ... the ninth time that the company received a perfect ... to Work for LGBT Equality. Administered by the Human ... report on corporate policies and practices related to workplace ... "We are committed to creating an ...
(Date:12/8/2016)... , Dec. 8, 2016  Avelas Biosciences, ... improving cancer patient care from diagnosis through treatment, ... recently completed Phase 1b study in breast cancer ... San Antonio Breast Cancer Symposium. Jonathan Unkart ... at UC San Diego Health, delivered the presentation ...
(Date:12/8/2016)... 2016  Hanson Research, an innovative leader in ... diffusion testing instruments for the pharmaceutical industry, announced ... Inc. ("Teledyne"). The move is designed to deepen ... instruments, as well as expand resources for further ... and services. Logo - http://photos.prnewswire.com/prnh/20161208/446988LOGO ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle ... in Jefferson County, is announcing the launch of a charity drive to raise ... of homeless women and children in Birmingham has grown steadily since the 1980’s, ...
(Date:12/8/2016)... ... 08, 2016 , ... The Compretta Insurance Agency, a family owned insurance and ... the Hancock County area, is announcing the launch of a charity effort aimed at ... County Food Pantry has worked for more than 30 years to meet the food ...
(Date:12/7/2016)... OF PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... clinical trials with the announcement that it is one of the early adopters completing ... Privacy Shield Framework is designed to provide companies on both sides of the Atlantic ...
(Date:12/7/2016)... Wisconsin (PRWEB) , ... December 07, 2016 , ... Kenall ... extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire ... right amount of light where and when it’s needed. , A 2’ ...
(Date:12/7/2016)... ... December 07, 2016 , ... Wavelink, an industry leader ... through a new partnership with Splashtop Inc. This remote control for Android extends ... help businesses maximize their uptime and productivity. , Wavelink offers powerful enterprise mobility ...
Breaking Medicine News(10 mins):